{"entity":{"id":"nct03697707","kind":"trial","name":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia","aka":[],"tldr":"A phase 2 trial of Vididencel run by Mendus, of unknown status on the registry.","summary":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia is a phase 2 interventional study registered as NCT03697707 by Mendus, with 20 participants planned, started 2018-10-15. Conditions recorded: Acute Myeloid Leukemia in Remission. Interventions recorded: DCP-001.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03697707","url":"https://clinicaltrials.gov/study/NCT03697707"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["vididencel"],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03697707","phase":"2","setting":"An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD","sponsor":"Mendus","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03697707/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"vididencel","kind":"drug","name":"Vididencel","route":"/drugs/vididencel/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}]}}